Market closedADR
Legend Biotech/$LEGN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Legend Biotech
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Ticker
$LEGN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
2,400
Website
Legend Biotech Metrics
BasicAdvanced
$6.3B
Market cap
-
P/E ratio
-$1.92
EPS
0.08
Beta
-
Dividend rate
Price and volume
Market cap
$6.3B
Beta
0.08
52-week high
$70.13
52-week low
$32.50
Average daily volume
1.6M
Financial strength
Current ratio
4.984
Quick ratio
4.859
Long term debt to equity
30.665
Total debt to equity
31.054
Interest coverage (TTM)
-15.76%
Management effectiveness
Return on assets (TTM)
-12.28%
Return on equity (TTM)
-28.35%
Valuation
Price to revenue (TTM)
11.953
Price to book
5.6
Price to tangible book (TTM)
5.61
Price to free cash flow (TTM)
-35.293
Growth
Revenue change (TTM)
122.96%
Earnings per share change (TTM)
-35.35%
3-year revenue growth (CAGR)
77.21%
3-year earnings per share growth (CAGR)
-9.57%
What the Analysts think about Legend Biotech
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Legend Biotech stock.
Legend Biotech Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Legend Biotech Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Legend Biotech News
AllArticlesVideos
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire·3 days ago
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
GlobeNewsWire·2 weeks ago
Legend Biotech: The Story Brightens
Seeking Alpha·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Legend Biotech stock?
Legend Biotech (LEGN) has a market cap of $6.3B as of December 22, 2024.
What is the P/E ratio for Legend Biotech stock?
The price to earnings (P/E) ratio for Legend Biotech (LEGN) stock is 0 as of December 22, 2024.
Does Legend Biotech stock pay dividends?
No, Legend Biotech (LEGN) stock does not pay dividends to its shareholders as of December 22, 2024.
When is the next Legend Biotech dividend payment date?
Legend Biotech (LEGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Legend Biotech?
Legend Biotech (LEGN) has a beta rating of 0.08. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.